Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner

Nature Communications

Volumn 5, Issue , 2014, Pages

  Elgendy, Mohamed ^a   Ciro, Marco ^a   Abdel Aziz, Amal Kamal ^a,d   Belmonte, Giuseppe ^b   Zuffo, Roberto Dal ^a   Mercurio, Ciro ^a   Miracco, Clelia ^b   Lanfrancone, Luisa ^a   Foiani, Marco ^a,c   Minucci, Saverio ^a,c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d African Union Organization St Abbassia   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BECLIN 1; DEUBIQUITINASE; DOXYCYCLINE; PROTEASOME; PROTEIN MCL 1; PROTEIN USP9X; ROSCOVITINE; SORAFENIB; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; BECN1 PROTEIN, MOUSE; MCL1 PROTEIN, HUMAN; MCL1 PROTEIN, MOUSE; MEMBRANE PROTEIN; UBIQUITIN THIOLESTERASE; USP9X PROTEIN, HUMAN;

APOPTOSIS; BIODEGRADATION; CANCER; CELL ORGANELLE; PROTEIN; STABILIZATION; TUMOR;

ARTICLE; AUTOPHAGY; CANCER GROWTH; CARCINOGENESIS; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOMA CELL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RNA TRANSLATION; UBIQUITINATION; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; HAPLOINSUFFICIENCY; HEK293 CELL LINE; HELA CELL LINE; MELANOMA; METABOLISM; MOUSE; PATHOLOGY; SECONDARY; SKIN TUMOR; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CARCINOGENESIS; HAPLOINSUFFICIENCY; HEK293 CELLS; HELA CELLS; HUMANS; MELANOMA; MEMBRANE PROTEINS; MICE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASM TRANSPLANTATION; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; UBIQUITIN THIOLESTERASE;

EID: 84923378545     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6637     Document Type: Article

References (37)

1. Aichberger, K. J. et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105, 3303-3311 (2005).
2. Campbell, K. J. et al. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Blood 116, 3197-3207 (2010).
3. Cho-Vega, J. H. et al. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum. Pathol. 35, 1095-1100 (2004).
4. Khoury, J. D. et al. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J. Pathol. 199, 90-97 (2003).
5. Wuillème-Toumi, S. et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19, 1248-1252 (2005).
6. Zhou, P. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood 97, 3902-3909 (2001).
7. Schwickart, M. et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463, 103-107 (2010).
8. Perciavalle, R. M. et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat. Cell Biol. 14, 575-583 (2012).
9. Bolesta, E. et al. Inhibition of Mcl-1 promotes senescence in cancer cells: implications for preventing tumor growth and chemotherapy resistance. Mol. Cell Biol. 32, 1879-1892 (2012).
10. Maiuri, M. C. et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J. 26, 2527-2539 (2007).
11. Elgendy, M. et al. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol. Cell 42, 23-35 (2011).
12. Akgul, C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell. Mol. Life Sci. 66, 1326-1336 (2009).
13. Dash, R. et al. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc. Natl Acad. Sci. USA 108, 8785-8790 (2011).
14. Gores, G. J. & Kaufmann, S. H. Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev. 26, 305-311 (2012).
15. Jackson, R. S. et al. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia 14, 656-665 (2012).
16. Quinn, B. A. et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin. Investig. Drugs 20, 1397-1411 (2011).
17. Warr, M. R. & Shore, G. C. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr. Mol. Med. 8, 138-147 (2008).
18. Aita, V. M. et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 59, 59-65 (1999).
19. Liang, X. H. et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402, 672-676 (1999).
20. Qu, X. et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J. Clin. Invest. 112, 1809-1820 (2003).
21. Miracco, C. et al. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions. Hum. Pathol. 41, 503-512 (2010).
22. Liu, J. et al. Beclin 1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 147, 223-234 (2011).
23. Wirawan, E. et al. Beclin 1: a role in membrane dynamics and beyond. Autophagy 8, 6-17 (2012).
24. Germain, M. et al. MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner. EMBO J. 30, 395-407 (2011).
25. Zhong, Q., Gao, W., Du, F. & Wang, X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121, 1085-1095 (2005).
26. Czabotar, P. E. et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc. Natl Acad. Sci. USA 104, 6217-6222 (2007).
27. Bonapace, L. et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J. Clin. Invest. 120, 1310-1323 (2010).
28. Zhuang, L. et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol. 20, 416-426 (2007).
29. Jiang, C. C. et al. Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res. 68, 6708-6717 (2008).
30. Boisvert-Adamo, K., Longmate, W., Abel, E. V. & Aplin, A. E. Mcl-1 is required for melanoma cell resistance to anoikis. Mol. Cancer Res. 7, 549-556 (2009).
31. Skvara, H. et al. Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death. Anticancer Res. 25, 2697-2703 (2005).
32. Chetoui, N. et al. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol. Cancer Res. 6, 42-52 (2008).
33. Thallinger, C. et al. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J. Invest. Dermatol. 120, 1081-1086 (2003).
34. Keuling, A. M. et al. RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a Caspase-8-dependent pathway. PLoS ONE 4, e6651 (2009).
35. Inuzuka, H. et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471, 104-109 (2011).
36. Rosenfeldt, M. T. & Ryan, K. M. The role of autophagy in tumour development and cancer therapy. Expert Rev. Mol. Med. 11, e36 (2009).
37. Pérez-mancera, P. A. et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486, 266-270 (2012).